Transcatheter mitral valve replacement is an emerging catheter-based technology designed to replace a severely diseased mitral valve without open-heart surgery. While still primarily available through clinical trials, TMVR represents the next frontier in structural heart innovation.
TMVR aims to do for the mitral valve what TAVR has done for the aortic valve — provide a less invasive alternative to open surgical repair or replacement. A prosthetic valve is delivered via catheter and implanted within the native mitral valve (or within a previously implanted surgical valve or ring that has failed).
The mitral valve is a more complex structure than the aortic valve — it has two leaflets, an intricate subvalvular apparatus (chordae tendineae and papillary muscles), and an asymmetric, saddle-shaped annulus. These anatomic challenges make TMVR significantly more technically demanding than TAVR, which is why the field has developed more gradually.
Several TMVR devices are in various stages of clinical development. The most advanced programs include the Tendyne (Abbott), Evoque (Edwards Lifesciences), and Intrepid (Medtronic) systems. Some devices are delivered transapically (through a small incision between the ribs directly into the heart's apex), while others use a transfemoral (groin) or transseptal approach. Each design takes a different approach to anchoring the valve, managing the subvalvular apparatus, and preventing obstruction of blood flow out of the heart (left ventricular outflow tract obstruction, or LVOTO).
One area where transcatheter mitral technology is already FDA-approved is valve-in-valve and valve-in-ring procedures — implanting a transcatheter valve inside a previously surgically placed mitral bioprosthesis or annuloplasty ring that has deteriorated. This avoids the need for a second open-heart surgery and is performed using commercially available TAVR valves (such as the Sapien system) deployed in the mitral position.
TMVR is primarily being studied for patients with severe mitral regurgitation who are poor candidates for surgery and whose anatomy may not be suitable for edge-to-edge repair (TEER). This includes patients with complex valve anatomy, significant annular calcification, or prior failed repair. As the technology matures, indications may expand to broader patient populations.
Because TMVR is currently available primarily through clinical trials, the experience varies by device and approach. In general, the procedure is performed under general anesthesia with echocardiographic guidance. Hospital stays are typically 3–7 days depending on the approach and patient's baseline health. Recovery is faster than open surgery but generally longer than TEER given the complexity of the procedure.
Key risks include LVOT obstruction (blocking blood flow out of the heart — a challenge unique to the mitral position), paravalvular leak, device migration, vascular or access site complications, and the need for a permanent pacemaker. Because this is an evolving technology, long-term durability data is still being gathered. Patients considering TMVR should discuss participation in a clinical trial with their structural heart team.